Skip to main content
Top
Published in: Journal of Nephrology 1/2024

14-06-2023 | Clostridium | Case Report

Clostridium septicum infection complicating Hemolytic-Uremic Syndrome: a case report and review of the literature

Authors: Luigi Cirillo, Alice Noris, Ludovica Odone, Flavio Giordano, Francesca Becherucci

Published in: Journal of Nephrology | Issue 1/2024

Login to get access

Abstract

Clostridium septicum (C. septicum) is a zoonotic bacillus found in 2.8% of healthy human stools. In humans, it can cause serious infections such as bacteremia, myonecrosis, and encephalitis by spreading through the bloodstream. Reports of Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome complicated by C. septicum superinfection are rare, likely because colonic microangiopathic lesions by Shiga toxin-producing Escherichia Coli facilitate bacterial dissemination. Only 13 cases of Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome with C. septicum superinfection have been reported to date, according to our litterature review, with a 50% mortality rate. The lack of clinico-laboratory clues suggesting this condition makes the diagnosis challenging. For these reasons C. septicum superinfection usually goes undiagnosed in patients with Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome, and results in unfavorable outcomes. In this paper, we describe the case of a 5-year-old girl admitted for Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome who developed C. septicum coinfection leading to a fatal outcome. We carried out a review of the available literature on C. septicum infection complicating Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome and we compared the clinical features of the observed cases with those of an historical cohort of uncomplicated Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome. The mechanisms of superinfection are still unclear and clinical features are indistinguishable from those of uncomplicated Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome. However, rapid deterioration of clinical conditions and evidence of neurological involvement, associated with abnormal radiological findings, require immediate management. Although therapeutic approaches have not been directly compared, neurosurgical treatment of amenable lesions may improve the clinical outcome of patients with C. septicum-hemolytic-uremic syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hitchcock CR, Demello FJ, Haglin JJ (1975) Gangrene infection: new approaches to an old disease. Surg Clin North Am 55:1403–1410CrossRefPubMed Hitchcock CR, Demello FJ, Haglin JJ (1975) Gangrene infection: new approaches to an old disease. Surg Clin North Am 55:1403–1410CrossRefPubMed
3.
12.
go back to reference Tarr PI, Karpman D (2012) Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins. Clin Infect Dis 55:760–763CrossRefPubMed Tarr PI, Karpman D (2012) Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins. Clin Infect Dis 55:760–763CrossRefPubMed
Metadata
Title
Clostridium septicum infection complicating Hemolytic-Uremic Syndrome: a case report and review of the literature
Authors
Luigi Cirillo
Alice Noris
Ludovica Odone
Flavio Giordano
Francesca Becherucci
Publication date
14-06-2023
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2024
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01641-9

Other articles of this Issue 1/2024

Journal of Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine